These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Walton M; Sharif S; Simmonds M; Claxton L; Hodgson R Pharmacoeconomics; 2019 Oct; 37(10):1209-1217. PubMed ID: 30982165 [TBL] [Abstract][Full Text] [Related]
23. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. Ghorashian S; Jacoby E; De Moerloose B; Rives S; Bonney D; Shenton G; Bader P; Bodmer N; Quintana AM; Herrero B; Algeri M; Locatelli F; Vettenranta K; Gonzalez B; Attarbaschi A; Harris S; Bourquin JP; Baruchel A Lancet Haematol; 2022 Oct; 9(10):e766-e775. PubMed ID: 36084658 [TBL] [Abstract][Full Text] [Related]
25. Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection. Hall EM; Yin DE; Goyal RK; Ahmed AA; Mitchell GS; St Peter SD; Flatt TG; Ahmed IA; Li W; Hendrickson RJ; August KJ; Myers GD J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472856 [TBL] [Abstract][Full Text] [Related]
26. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. Schultz LM; Eaton A; Baggott C; Rossoff J; Prabhu S; Keating AK; Krupski C; Pacenta H; Philips CL; Talano JA; Moskop A; Baumeister SHC; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston M; Satwani P; Wilcox R; Rabik CA; Fabrizio VA; Chinnabhandar V; Kunicki M; Mavroukakis S; Egeler E; Li Y; Mackall CL; Curran KJ; Verneris MR; Laetsch TW; Stefanski H J Clin Oncol; 2023 Jan; 41(2):354-363. PubMed ID: 36108252 [TBL] [Abstract][Full Text] [Related]
27. Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia. Ma Q; Zhang J; O'Brien E; Martin AL; Agostinho AC J Comp Eff Res; 2020 Aug; 9(12):849-860. PubMed ID: 32602756 [No Abstract] [Full Text] [Related]
28. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. Kansagra AJ; Frey NV; Bar M; Laetsch TW; Carpenter PA; Savani BN; Heslop HE; Bollard CM; Komanduri KV; Gastineau DA; Chabannon C; Perales MA; Hudecek M; Aljurf M; Andritsos L; Barrett JA; Bachanova V; Bonini C; Ghobadi A; Gill SI; Hill J; Kenderian S; Kebriaei P; Nagler A; Maloney D; Liu HD; Shah NN; Kharfan-Dabaja MA; Shpall EJ; Mufti GJ; Johnston L; Jacoby E; Bazarbachi A; DiPersio JF; Pavletic SZ; Porter DL; Grupp SA; Sadelain M; Litzow MR; Mohty M; Hashmi SK Biol Blood Marrow Transplant; 2019 Mar; 25(3):e76-e85. PubMed ID: 30576834 [TBL] [Abstract][Full Text] [Related]
29. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832 [TBL] [Abstract][Full Text] [Related]
30. Tisagenlecleucel (Kymriah) for ALL. Med Lett Drugs Ther; 2017 Oct; 59(1532):177-178. PubMed ID: 29039821 [No Abstract] [Full Text] [Related]
33. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients. Asare JM; Rabik CA; Muller B; Brown PA; Cooper S Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328 [No Abstract] [Full Text] [Related]
34. Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia. Hiramatsu H; Adachi S; Umeda K; Kato I; Eldjerou L; Agostinho AC; Natsume K; Tokushige K; Watanabe Y; Grupp SA Int J Hematol; 2020 Feb; 111(2):303-310. PubMed ID: 31709501 [TBL] [Abstract][Full Text] [Related]
35. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia? Zhang M; Huang H Front Immunol; 2020; 11():611710. PubMed ID: 33384696 [TBL] [Abstract][Full Text] [Related]
36. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia. Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090 [TBL] [Abstract][Full Text] [Related]
37. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective. Yang H; Hao Y; Qi CZ; Chai X; Wu EQ J Manag Care Spec Pharm; 2020 Aug; 26(8):971-980. PubMed ID: 32525730 [TBL] [Abstract][Full Text] [Related]
38. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422 [TBL] [Abstract][Full Text] [Related]
39. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018 [TBL] [Abstract][Full Text] [Related]
40. Paving the road ahead for CD19 CAR T-cell therapy. Nellan A; Lee DW Curr Opin Hematol; 2015 Nov; 22(6):516-20. PubMed ID: 26335422 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]